TA
OREX

Teachers Advisors’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Teachers Advisors’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-31,224
Closed -$176K – 3260
2016
Q1 		$176K Hold
31,224
– – ﹤0.01% 2822
2015
Q4 		$537K Buy
31,224
+988
+3% +$23.6K ﹤0.01% 2365
2015
Q3 		$638K Sell
30,236
-91
-0.3% -$3.12K ﹤0.01% 2240
2015
Q2 		$1.5M Sell
30,327
-19,809
-40% -$1.18M ﹤0.01% 1871
2015
Q1 		$3.93M Buy
50,136
+9,454
+23% +$586K 0.01% 1266
2014
Q4 		$2.46M Buy
40,682
+14,160
+53% +$711K ﹤0.01% 1503
2014
Q3 		$1.13M Sell
26,522
-48,526
-65% -$2.61M ﹤0.01% 1943
2014
Q2 		$4.64M Buy
75,048
+5,953
+9% +$346K 0.01% 1161
2014
Q1 		$4.49M Sell
69,095
-13,499
-16% -$913K 0.01% 1143
2013
Q4 		$4.65M Buy
82,594
+4,420
+6% +$248K 0.01% 1128
2013
Q3 		$4.8M Buy
78,174
+532
+0.7% +$36K 0.01% 1047
2013
Q2 		$4.54M Buy
+77,642
New +$4.78M 0.01% 1034

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Teachers Advisors's OREX Position: Q2 2016 in Review

Teachers Advisors sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2016, closing a stake of 31,224 shares — an estimated $176K sold.

Teachers Advisors first reported a position in OREX in Q2 2013 and held it in 12 quarters. The position peaked at $4.8M in Q3 2013. 73 funds tracked by Wall St. Rank hold OREX as of Q2 2016.

  • Teachers Advisors reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
  • Teachers Advisors sold 31,224 Orexigen Therapeutics, Inc. shares in Q2 2016, an estimated $176K.
  • Teachers Advisors first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 12 quarters.
  • Teachers Advisors's Orexigen Therapeutics, Inc. position peaked at $4.8M in Q3 2013.
  • 73 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2016.

Based on Teachers Advisors's 13F filing for Q2 2016, filed 11 Aug 2016.